Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death

被引：0
|
作者：
Sortais, C. [1 ]
Lok, A. [1 ]
Gastinne, T. [1 ]
Mahe, B. [1 ]
Dubruille, V. [1 ]
Blin, N. [1 ]
Howlett, S. [2 ]
Tabah, A. [2 ]
Arnaud, P. [2 ]
Moreau, A. [3 ]
Moreau, P. [1 ]
Leux, C. [4 ]
Le Gouill, S. [1 ]
机构：
[1] CHU Nantes, Serv Hematol Clin, Nantes, France
[2] Celgene Med, Lymphoma Dept, Summit, NJ USA
[3] CHU Nantes, Serv Anatomopathol, Nantes, France
[4] CHU Nantes, Serv Informat Med, Nantes, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1018P
引用
收藏
页码：364 / 364
页数：1
相关论文
共 35 条
  • [1] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Sortais, Clara
    Lok, Anne
    Tessoulin, Benoit
    Gastinne, Thomas
    Mahe, Beatrice
    Dubruille, Viviane
    Blin, Nicolas
    Touzeau, Cyrille
    Moreau, Anne
    Bossard, Celine
    Peterlin, Pierre
    Garnier, Alice
    Guillaume, Thierry
    Le Bourgeois, Amandine
    Chevallier, Patrice
    Moreau, Philippe
    Leux, Christophe
    Le Gouill, Steven
    ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1595 - 1604
  • [2] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Clara Sortais
    Anne Lok
    Benoit Tessoulin
    Thomas Gastinne
    Béatrice Mahé
    Viviane Dubruille
    Nicolas Blin
    Cyrille Touzeau
    Anne Moreau
    Céline Bossard
    Pierre Peterlin
    Alice Garnier
    Thierry Guillaume
    Amandine Le Bourgeois
    Patrice Chevallier
    Philippe Moreau
    Christophe Leux
    Steven Le Gouill
    Annals of Hematology, 2020, 99 : 1595 - 1604
  • [3] Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)
    Hamid, Muhammad Saad
    Bai, Claire
    Perelgut, Chelsea
    Yelovich, Helena
    Zettler, Christina M.
    Fernandes, Laura L.
    Belli, Andrew J.
    Hansen, Eric
    Wang, Ching-Kun
    BLOOD, 2023, 142
  • [4] Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
    Marie Hairing Enemark
    Jonas Klejs Hemmingsen
    Maja Dam Andersen
    Trine Engelbrecht Hybel
    Mads Emil Bjørn
    Pär Lars Josefsson
    Lars Møller Pedersen
    Maja Bech Juul
    Robert Schou Pedersen
    Michael Thorsgaard
    Ida Blok Sillesen
    Trine Lindhardt Plesner
    Stephen Jacques Hamilton-Dutoit
    Paw Jensen
    Charlotte Madsen
    Maja Ludvigsen
    Blood Cancer Journal, 14 (1)
  • [5] Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status
    Merryman, Reid W.
    Belada, David
    Sureda, Anna
    Leppa, Sirpa
    Vermaat, Joost S. P.
    Holte, Harald
    Hutchings, Martin
    Lugtenburg, Pieternella
    de Vos, Sven
    Abrisqueta, Pau
    Nijland, Marcel
    Christensen, Jacob Haaber
    Wahlin, Bjorn E.
    Linton, Kim M.
    Wang, Liwei
    Abbas, Aqeel
    Rana, Ali
    Quadri, Syed
    Falchi, Lorenzo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S454
  • [6] Frontline therapy with Bendamustine and rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma
    Freeman, Ciara Louise
    Savage, Kerry J.
    Villa, Diego
    Scott, David W.
    Gerrie, Alina S.
    Ferguson, David J.
    Cafferty, Fergus
    Slack, Graham W.
    Farinha, Pedro
    Skinnider, Brian
    Connors, Joseph M.
    Sehn, Laurie H.
    BLOOD, 2018, 132
  • [7] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
    Fenghua Gao
    Tingting Zhang
    Hengqi Liu
    Wei Li
    Xianming Liu
    Lihua Qiu
    Lanfang Li
    Shiyong Zhou
    Zhengzi Qian
    Sitong Dong
    Sai Zhao
    Xianhuo Wang
    Huilai Zhang
    Annals of Hematology, 2022, 101 : 2383 - 2392
  • [8] Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
    Merryman, Reid
    Belada, David
    Sureda, Anna
    Leppa, Sirpa
    Vermaat, Joost S. P.
    Holte, Harald
    Hutchings, Martin
    Lugtenburg, Pieternella
    de Vos, Sven
    Abrisqueta, Pau
    Nijland, Marcel
    Christensen, Jacob Haaber
    Wahlin, Bjorn E.
    Linton, Kim M.
    Wang, Liwei
    Abbas, Aqeel
    Rana, Ali
    Quadri, Syed
    Falchi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
    Gao, Fenghua
    Zhang, Tingting
    Liu, Hengqi
    Li, Wei
    Liu, Xianming
    Qiu, Lihua
    Li, Lanfang
    Zhou, Shiyong
    Qian, Zhengzi
    Dong, Sitong
    Zhao, Sai
    Wang, Xianhuo
    Zhang, Huilai
    ANNALS OF HEMATOLOGY, 2022, 101 (11) : 2383 - 2392
  • [10] Correction to: Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta‑analysis
    Fenghua Gao
    Tingting Zhang
    Hengqi Liu
    Wei Li
    Xianming Liu
    Lihua Qiu
    Lanfang Li
    Shiyong Zhou
    Zhengzi Qian
    Sitong Dong
    Sai Zhao
    Xianhuo Wang
    Huilai Zhang
    Annals of Hematology, 2022, 101 : 2817 - 2817
1234